AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
Up The Antibodies is a first-of-its-kind educational campaign to support the immunocompromised community and raise awareness of their options to prevent COVID-19, including a long-acting monoclonal antibody
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220915005056/en/
Up The Antibodies, a new educational campaign from
A recent study published by the
However, awareness of the unmet need and these options is still low, and that is the reason behind the creation of Up The Antibodies. To launch the campaign,
"A lot of the world is trying to move forward and put COVID-19 behind them, but people with compromised immune systems can't do that yet," said Bridges. "That's why this partnership with
Jeff's battle with COVID-19 almost cost him his life, so it was fitting that, for this PSA, he was able to get back to doing what he loves with some of his favorite people - joining director
"While the option to up my antibodies to protect me from COVID-19 wasn't around when I was going through cancer treatment, it is now. As soon as I could, I upped my antibodies," Bridges said. "And now I'm feeling more confident to get back to doing the things I love."
Just as Up The Antibodies aims to let immunocompromised people know they aren't alone, Bridges isn't alone in this campaign. Actor, producer, and Academy Award-nominated writer
"Surviving a coma from adult-onset Still's disease was terrifying. I never want to go through something like that again. So, with the arrival of the COVID-19 epidemic, we both knew we had to be more careful than ever before," said Gordon. "Our experiences are so similar to what so many people who are immunocompromised are going through and we are thankful for the opportunity to share our experiences to educate others, so they can talk with their doctors about their options."
Nanjiani adds, "At the start of the pandemic, I suffered panic attacks for the first time in my life because I was so worried about Emily, and now, while we have learned to navigate together, it never gets easier. Decisions are often made together, which is why it's important for everyone to know that there is the option to add protection in addition to vaccines and boosters, wearing a mask and social distancing to prevent COVID-19."
From the outset of this initiative,
"At AstraZeneca, we believe it is our unique responsibility to support and empower the immunocompromised community, offering hope while the rest of the world strives to return to a sense of normalcy," said
Visit UpTheAntibodies.com to view additional content from Bridges, Nanjiani and Gordon. The campaign website also includes information on long-acting monoclonal antibodies and essential resources, including a patient and doctor conversation guide. Campaign followers are encouraged to join Up The Antibodies social channels to engage with others in the immunocompromised community and share experiences navigating the pandemic.
About Up The Antibodies
Up The Antibodies is an educational campaign for those who are immunocompromised about steps they can take to get an added layer of protection to prevent COVID-19 including with a long-acting monoclonal antibody therapy option. While the development of vaccines allowed many Americans to get back to normal, COVID-19 has continued to hold back people who are immunocompromised and who may not receive adequate protection from vaccines alone.5 Up The Antibodies serves as a call to action, reminding this community that when you up your antibodies, it can offer a renewed sense of hope to get back to the little things in life that you enjoy the most. Visit UpTheAntibodies.com to access additional information and resources, and follow Up The Antibodies on social media, including Facebook, Twitter and Instagram.
About Long-Acting Monoclonal Antibody Therapy
Monoclonal antibody therapy was one of the first tools used to treat COVID-19.6 For those who are immunocompromised/immune compromised, monoclonal antibody therapy can offer additional protection on top of vaccinations to help protect the most vulnerable.4 Monoclonal antibodies are produced in a laboratory to mimic or enhance the immune system's response.7 They recognize, bind to and neutralize specific viruses and other pathogens.4
- Harpaz R, Dahl RM, Dooling KL. Prevalence of Immunosuppression Among US Adults, 2013. JAMA. 2016;316(23):2547-2548. doi: 10.1001/jama.2016.16477. Accessed
June 15, 2022.
- US Census Bureau Public Information Office. (2013,
May 19). Census Bureauprojects U.S.population of 315.1 million on New Year's day- population - newsroom - U.S. Census Bureau. https://www.census.gov/newsroom/releases/archives/population/cb12-255.html. Accessed August 26, 2022.
- Singson JR, Kirley PD, Pham H, et al. Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 -- COVID-NET, 10 States, March 2020-February 2022. MMWR Morb Mortal Wkly Rep. 2022;71:878-884. doi:http://dx.doi.org/10.15585/mmwr.mm7127a3. Accessed
July 19, 2022.
- Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21(6):382-393. doi:10.1038/s41577-021-00542-x. Accessed
June 15, 2022.
- Haidar G, Agha M, Bilderback A, et al. Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study [published online ahead of print, 2022 Feb 18]. Clin Infect Dis. 2022; 75(1):e630-e644. doi:10.1093/cid/ciac103. Accessed
June 13, 2022.
- Minnich A, Rocha D, Hu Y, Boell K, Burke GF. Delivering monoclonal antibody infusions to novel outpatient settings. NEJM Catalyst Innovations in Care Delivery 2022. https://doi.org/10.1056/CAT.21.0463. Accessed
August 26, 2022.
- Lloyd EC, Gandhi TN, Petty LA. Patient information: Monoclonal antibodies for COVID-19. JAMA. https://jamanetwork.com/journals/jama/fullarticle/2776307. Published
March 9, 2021. Accessed July 13, 2022.
US Media Mailbox: [email protected]